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Cryptococcosis caused by Cryptococcus neoformans and Cryptococcus gattii affects
a large population and is a cause of significant morbidity and mortality. Despite its
public health burden, there are currently no vaccines against cryptococcosis and new
strategies against such infections are needed. In this study, we demonstrate that C.
neoformans has the biochemical ability to metabolize sterylglucosides (SGs), a class
of immunomodulatory glycolipids. Genetic manipulations that eliminate cryptococccal
sterylglucosidase lead to the accumulation of SGs and generate a mutant strain (sgl1)
that is non-pathogenic in the mouse models of cryptococcosis. Interestingly, this mutant
strain acts as a vaccine strain and protects mice against cryptococcosis following
infection with C. neoformans or C. gattii. The immunity induced by the sgl1 strain
is not CD4+ T-cells dependent. Immunocompromised mice, which lack CD4+ T-cells,
are able to control the infection by sgl1 and acquire immunity against the challenge by
wild-type C. neoformans following vaccination with the sgl1 strain. These findings are
particularly important in the context of HIV/AIDS immune deficiency and suggest that
the sgl1 strain might provide a potential vaccination strategy against cryptococcosis.
Keywords: yeast genetics, gene expression, glycolipid, immunosuppression, vaccine development
Introduction
Cryptococcus is an opportunistic fungal pathogen and the causative agent of the disease
cryptococcosis. Infections caused by Cryptococcus neoformans and Cryptococcus gattii lead to
more than 600000 deaths per year (Park et al., 2009), especially among immunocompromised
individuals. Despite its signiﬁcant public health burden, no vaccines currently exist in the clinic
for cryptococcosis (or other fungal infections Nanjappa and Klein, 2014). Although experimental
vaccines have been developed using the glucuronoxylomannan (GXM) capsule bound to tetanus
toxoid (Devi et al., 1991; Casadevall et al., 1992; Devi, 1996), these formulations have not
been translated to the clinic and have suﬀered from drawbacks such as inducing detrimental
antibodies in mice (Casadevall and Pirofski, 2005; Datta and Pirofski, 2006). Recent attempts
in the mouse models of cryptococcosis have been focused on the use of genetically engineered
C. neoformans strains that generate cytokines (Wormley et al., 2007; Wozniak et al., 2011) or
protein preparations from C. gattii administered prior to infection (Chaturvedi et al., 2014).
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Although these attempts have provided valuable insights, studies
are still limited and shortcomings exist. For example, complete
immunity against C. gattii (responsible for severe infections in
the USA Datta et al., 2009; Walraven et al., 2011) has not been
achieved (Chaturvedi et al., 2014) demonstrating the need for the
development of more eﬀective vaccines.
Sterylglucosides (SGs) are a class of glycolipids produced
by animals, plants, bacteria and various fungi including
C. neoformans (Warnecke et al., 1999; Watanabe et al., 2015).
SGs show immunomodulatory properties as reported by various
studies. For example, SGs have been shown to increase
proliferation of lymphocytes and eosinophils in vivo (Donald
et al., 1997) and cytokine secretion in vitro (Bouic et al., 1996;
Lee and Han, 2006; Lee et al., 2007). In the realm of fungal
infections, it has been observed that SGs administration increases
the survival of mice infected with a lethal dose of Candida
albicans by inducing a Th1 immune response (Lee et al., 2007).
A recent report has identiﬁed a endoglycoceramidase-
related protein (named EGCrP2), capable of hydrolyzing SGs
in C. neoformans (Watanabe et al., 2015). We hypothesized
that the lack of this enzyme should lead to a lack of SG
catabolism and subsequent SG accumulation, allowing for the
immunomodulatory properties of SGs to manifest. Thus, we
sought to utilize the immunomodulatory properties of fungal
SGs by engineering a C. neoformans strain that lacks the
sterylglucosidase enzyme. This strain was non-pathogenic in
the mouse models of cryptococcosis and conferred complete
protection against both C. neoformans and C. gattii, suggesting
that it might be a suitable candidate for vaccine development
against cryptococcosis.
Materials and Methods
Strains, Plasmid, and Culture Conditions
The fungal strains used in this study were C. neoformans (Cn) var.
grubii strain H99 wild-type (WT) and C. gattii strain R265 and
Saccharomyces cerevisiae YIR007W mutant (ScYIR) derived
from BY4741. Bacterial strain Escherichia coli DH5-α (Life
Technologies, Carlsbad, CA, USA) was used as competent cells.
The plasmid pCR II-TOPO 4.0 kb was used for cloning, and
pYES2/CT was used for expression of Cn 5607 in ScYIR.
Bacterial strains were grown at 37◦C in Luria-Bertani medium
with 75 mg/L of ampicillin. Cn strains were routinely grown
in YPD broth at 30◦C and 0.04% atmospheric CO2 for 20–
22 h with shaking at 250 rpm. Dulbecco’s modiﬁed eagle media
(DMEM) buﬀered with 25 mM HEPES and 2% glucose at pH
7.4 or pH 4 was used for growing Cn at 37◦C and 5% CO2 (i.e.,
physiologically relevant conditions). ScYIR strain transformed
with pYES2/CT or pYES2/CT- Cn 5607, was grown in yeast
nitrogen base (YNB) without amino acids, 1.2 g/L amino acid
mixture lacking uracil (ura-), and 2% glucose or 2% galactose
(48 h) at 30◦C to induce Cn 5607 expression.
Expression of Cn 5607 in S. cerevisiae
Cn 5607 was identiﬁed by blasting the Cn WT
endoglycoceramidase-related Protein 1 (EGCrP1) sequence
in Cn WT Broad Institute genome database [http://www.
broadinstitute.org/annotation/genome/cryptococcus_neoforma
ns/MultiHome.html]. Two sequences were found: one 100%
identical to EGCrP1 and another one with an E-value of
9e-57, located on chromosome 14 (Cn 5607). To express Cn
5607 in S. cerevisiae strains, total RNA was extracted from
Cn and the cDNA was synthesized from 1 μg of the total
RNA using SuperScript III RNase H-Reverse Transcriptase
(Life Technologies). PCR was performed using the cDNA as
a template and the following expression primers: PRSGL1-5′
forward (5′-GAGCTCATGCCTCCTCCACCAGAAGT-3′) and
PRSGL1-5′ reverse (5′-TCTAGAAGCAATAACGCATTCAGGA
CA-3′) carrying the restriction enzyme sites for SacI and XbaI
respectively. A 2,556-pb fragment was cloned into pCR II-TOPO
vector generating plasmid pCR- Cn 5607 and sequenced.
After digestion with SacI and XbaI, Cn 5607 was inserted into
pYES2/CT vector generating pYES2/CT-Cn 5607. ScYIR was
grown in YNB medium overnight at 30◦C and transformed with
pYES2/CT empty-vector or pYES2/CT-Cn 5607 using lithium
acetate transformation, as previously described (Kawai et al.,
2010). After transformation, cells were plated on YNB ura- plates
and incubated for 2–3 days in 30◦C incubator. Then, S. cerevisiae
colonies were patched with sterile toothpicks to fresh YNB ura-
plates. To verify the expression of Cn 5607, one single colony
containing pYES2/CT or pYES2/CT-Cn 5607 construct was
inoculated into 10 ml of YNB ura- containing 2% of glucose
and was grown overnight at 30◦C with shaking. The cells were
washed twice with PBS 1X and a suitable amount of overnight
culture necessary to obtain an OD600 of 0.4 was transferred to a
fresh YNB ura- medium containing 2% of galactose (induction
medium) and incubated for 48 h at 30◦C with shaking. After
48 h, the cells were washed and harvested by centrifugation at
3000g for 5 min at 4◦C, and the cell pellets was stored at −80◦C
until ready to be used.
Total proteins were extracted from S. cerevisiae strains as
previously described (Singh et al., 2011). Protein content was
assessed by the method of Bradford using bovine serum albumin
(Sigma-Aldrich, St. Louis, MO, USA) as a standard. Fifty
micrograms of S. cerevisiae proteins were loaded onto SDS-PAGE
and stained with Coomassie Brilliant Blue. Western Blot was
used to detect the expression of recombinant fusion protein using
Anti-His (C-term)-HRP antibody.
In Vitro Activity Assay of Cn 5607 Using
Standard Plants SGs and Purified Cn SGs
The in vitro Cn 5607 enzymatic assay was performed using
20 μg of standard SGs (puriﬁed from plants and commercially
available) or 10 μg of endogenously puriﬁed SGs as substrate
and ScYIR + empty vector or ScYIR-Cn 5607 as source
of enzyme. The decrease in the intensity of the SGs band
was monitored by thin layer chromatography (TLC). Plants
SGs were incubated with 200 μg of ScYIR + empty vector
or 50, 100, and 200 μg of ScYIR-Cn 5607 at 30◦C for
1 h. Endogenously puriﬁed Cn SGs were incubated with
200 μg of ScYIR + empty vector or 100 μg of ScYIR-
Cn 5607 at 30◦C for 1 h. The reactions were terminated
by the addition of 300 μl of CHCl3/MeOH (1:1 ratio), the
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lower phases were dried down, resuspended in 50 μl of
CHCl3/MeOH (2:1 ratio) and analyzed by TLC. Cn 5607
speciﬁcally cleaves SGs, thus we calledCn 5607 sterylglucosidase1
(Sgl1).
The pH dependence of Sgl1 was determined using as substrate
SGs in a pH range of 4.5–8 using the following buﬀers at the
ﬁnal concentration of 50 mM: sodium acetate (pH 4.5–5.0), MES
(pH 5.5–6.0), sodium phosphate (pH 6.5–7.0), and HEPES (pH
7.5–8.0). The optimal temperature of Sgl1 was determined in the
range from 25 to 37◦C. The eﬀect of detergents was assessed
using Triton X-100, Sodium Deoxycholate and CHAPS at the
concentration of 0.05, 0.15, and 0.3%.
In Vitro Activity Assay of Cn 5607 Using
NBD-C6-Glucosylceramide and Cn Long Chain
GlcCer
To verify the enzymatic activity of Cn 5607, we used diﬀerent
substrates: NBD-C6-glucosylceramide (NBD-C6-GlcCer;
Matreya, LLC, State-College, PA, USA) and Cn long chain
GlcCer. Brieﬂy, 200 μg of yeast proteins from ScYIR + empty
vector or ScYIR-Cn 5607 were incubated ﬁrst with 20 μM of
NBD-C6-Glucosylceramide and at 30◦C for 1 h in a ﬁnal reaction
volume of 100 μl. The production of NBD-C6-Ceramide was
identiﬁed as a ﬂuorescent band using a PhosphorImagerTM
860 STORM unit and ImageQuant analysis (GE Healthcare,
Rahway, NJ, USA) as previously described (Rittershaus et al.,
2006).
The in vitro Cn 5607 activity was also valuated using 10 μg
of Cn long chain GlcCer and 200 μg of ScYIR + empty
vector or ScYIR-Cn 5607 cell extracts. Cerezyme (10 μg),
generously provided by the Genzyme Corporation (Cambridge,
MA, USA), was used as positive control for the catalytic reaction.
The reactions were terminated by the addition of 300 μl of
CHCl3/MeOH (1:1 ratio), the samples were mixed and the
phases were separated by centrifugation at 3000g for 5 min.
The lower phases were dried down using a SPD 2010 SpeedVac
vacuum dryer (Thermo Electron Corp.). The dried samples were
resuspended in 50 μl of CHCl3/MeOH (2:1 ratio) and analyzed
by TLC on silica gel plate (EMD Millipore, Billerica, MA, USA)
developed with chloroform/methanol/water (65:25:4, v/v/v) and
stained with iodine and resorcinol. The in vitro activity assay
using Cn long chain GlcCer and ScYIR + empty vector or
ScYIR-Cn 5607 was also repeated with a longer incubation time
(4 h) and the results were evaluated by liquid chromatography–
mass spectrometry (LC–MS).
Disruption and Reconstitution of SGL1 Gene in
Cn
The SGL1 gene (locus number CNAG_05607 in C. neoformans
var. grubii serotype A genome database) was deleted using
NAT1 (Nourseothricin Acetyl transferase1) split marker.
A knockout cassette was generated containing a 1.035 bp
of the 5′ untranslated region (5′UTR) upstream of the
ATG start codon of the SGL1 gene and a 1.059 bp of the
3′UTR. The 5′UTR was ampliﬁed by PCR using H99 genomic
DNA as a template and the following primers: 5′UTR-F (5′-
GTCAAGCTAAGAGCTCCATTTGATCAGCGGGATTCT-3′)
and 5′UTR-R (5′-TCCACTCCGAACTAGTATCGCGTAAA
CGAAGAGGTG-3′), containing SacI and SpeI sites, respectively
(underlined). The 3′UTR was ampliﬁed by PCR using H99
genomic DNA as a template and the following primers:
3′UTR-F (5′-GTCAAGCTAATCTAGAAGCCCATTCTGGTT
GTTCTG-3′) and 3′UTR-R (5′-ACATCACACTTCTAGATTTA
GCGAGCCACGTTTTCT-3′). The ampliﬁed fragments were
cloned in pCR II-TOPO and sequenced, generating plasmid
pCR-5′UTR-TOPO and pCR-3′UTR-TOPO. NAT1 gene, which
confers resistance to the antibiotic nourseothricin (Werner
BioAgents, Jena, Germany), under the control of Cn actin
promoter was digested from the plasmid pCR-NAT1-TOPO
by SacI and SpeI and ligated with 5′UTR digested with the
same restriction enzyme generating pCR-5′UTR-NAT1-TOPO.
Finally, pCR-5′UTR-NAT-TOPO was digested by EcoRV
and ligated with 3′UTR generating the disruption cassette
pCR-5′UTR-NAT1-3′UTR-TOPO that was named psgl1.
The deletion scheme is illustrated in Supplementary Figure
S3A. Cn WT was transformed with the plasmid psgl1
using biolistic DNA delivery device, as described previously
(Toﬀaletti et al., 1993). Stable transformants were grown on
YPD plates containing 100 μg/ml of nourseothricin. Colonies
were chosen randomly and genomic DNA was isolated and
digested with EcoRV and KpnI for Southern blot analysis. The
DNA fragments were screened by probing with a fragment
of 5′UTR. Transformant #106 showing deletion of the SGL1
gene by insertion of the NAT1 was chosen and designated
sgl1 mutant strain. SGL1 gene was reintroduced back into
the sgl1 using the reconstitution cassette pSK-SGL1-HYG,
which had the Hygromycin B allele as selectable marker. The
reconstitution scheme is illustrated in Supplementary Figure
S3B. The plasmid pSK-SGL1-HYG was biolistically delivered into
sgl1. Homologous recombinants were screened by Southern
hybridization using a 800 bp fragment of the SGL1 open reading
frame as probes. Transformant #21 showing reconstitution of
SGL1 gene was designated sgl1+SGL1 reconstituted strain.
Wild-type, mutant, and reconstituted strains were
characterized for their growth proﬁle, capsule formation,
stress response, and intracellular growth. For growth proﬁle
studies, WT, sgl1, and sgl1+SGL1 reconstituted strains were
grown overnight in YPD at 30◦C, the cells were washed three
times with PBS, counted, and diluted to a ﬁnal density of 104
cells/ml in DMEM at pH 7.4 or pH 4 and incubated at 37◦C in
the presence of 5% CO2. Aliquots were taken at diﬀerent time
points, diluted, and plated in duplicates onto YPD agar plates for
assessment of CFUs. Capsule thickness and melanin production
were determined as previously described (Wang et al., 1995; Shea
et al., 2006). For oxidative stress studies, strains were spotted in
serial dilution (107, 106, 105, 104, 103) on YPD agar plates with
25 mM HEPES (pH 7 or pH 4) supplemented with 5 mM H2O2,
cells growth was assessed after incubation at 30◦C for 96 h.
Nitrosative stress response was studied by spotting the strains
in serial dilution (107, 106, 105, 104, 103) on YNB agar plates
with 25 mM succinate acid (pH 4) supplemented with 0.1 mM
NaNO2. Cell growth was assessed after 96 h of incubation at
30, 37◦C in atmospheric environment or 37◦C in the presence
of 5% CO2.
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Phagocytosis and intracellular killing studies were performed
in J774.16macrophage-like cells as previously described (Tripathi
et al., 2012). Brieﬂy, for phagocytosis experiments cells were
plated in a 96 well plate in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum (FBS).
C. neoformans cells were grown overnight in YPD at 30◦C. Cells
were washed twice in PBS and counted. Approximately 105 cells
in DMEM + FBS medium were opsonized with 10 μg/ml of
anti-GXM monoclonal antibody 18B7 (kindly provided by Dr.
Arturo Casadevall) and added to macrophage-like cells activated
with 50 units/ml of recombinant murine gamma interferon and
0.3 μg/ml of lipopolysaccharide at an eﬀector-to-target ratio of
1:1. After incubation for 2 h, extracellular C. neoformans cells
were washed with three changes of warm DMEM medium and
fresh medium. Then, 200 μl of sterile water was added to each
well and the macrophage-like cells were lysed by pipetting several
times. CFUs were analyzed by plating them on YPD agar plates
and the numbers of internalized fungal cells were reported.
Intracellular killing were performed in the same way with the
following change: extracellular C. neoformans cells were washed
oﬀ once 2 h after the initial incubation and another time after
24 h of incubation. Macrophage-like cells were lysed after 24 h by
pipetting several times and CFUs were analyzed by plating them
on YPD agar plates.
Lipid Analysis of Cryptococcus Strains by TLC
Total lipids from Cryptococcus strains were extracted, as
described previously (Singh et al., 2012). Brieﬂy, a single colony
of Cryptococcus strains was grown in 15 ml of YPD broth at 30◦C
for 20 h at 250 rpm. Cryptococcus cells (5 × 108) were placed in
a single glass tube to which the Mandala extraction buﬀer was
added (Mandala et al., 1995). Lipid extraction was performed
according to the methods of Bligh and Dyer (Bligh and Dyer,
1959) followed by base hydrolysis. One set of dried samples was
resuspended in 50μl of CHCl3/MeOH (2:1 ratio) and analyzed by
TLC developed with chloroform/methanol/water (65:25:4, v/v/v)
and stained with iodine and resorcinol, the other set was used for
gas chromatography–mass spectrometry (GC–MS).
Lipid Profiling by Mass Spectrometry
Total lipids were extracted from Cryptococcus strains,
using the methods described previously (Singh et al.,
2012). For sterylglucosides analyses, extracted lipid
samples were derivatized using N, O-bis (trimethylsilyl)
triﬂuoroacetamide/trimethylchlorosilane reagent (Sigma-
Aldrich) and then analyzed using 30 mt (0.25 μm) DB5-MS
column on Agilent 7890 GC–MS (Agilent Technologies, Santa
Clara, CA, USA). The retention time and mass spectral patterns
of plant SGs standard (Avanti Polar Lipids, Inc., Alabaster, AL,
USA) were used as a reference (Gutierrez and del Rio, 2001).
Cholesterol was added as an internal standard for these analyses
prior to lipid extraction. Ceramide and glucosylceramide species
were analyzed by multiple reactions monitoring (MRM) as
described previously (Singh et al., 2012) using TSQ Quantum
UltraTM Triple Quadrupole Mass Spectrometer (Thermo
Scientiﬁc, USA). Samples were delivered by Accela pump
(Thermo Finnigan, USA) to the HPLC ﬁtted with 3 μm C8SR,
150 mm × 3.0 mm column (Peeke Scientiﬁc, Sommerset, NJ,
USA). C17 sphingosine and C17 ceramide were added as an
internal standard for these analyses prior to lipid extraction.
Determination of plant sterols and sterylglucosides for enzymatic
activity assay was performed using MRMmonitoring on LC–MS
(Wewer et al., 2011). Standard plant sterols and sterylglucosides
(Avanti Polar Lipids, Inc.) were used as the external standards in
these measurements.
Animal Studies
Four weeks old female CBA/J mice (Harlan Laboratories,
Indianapolis, IN, USA) were used for all studies. Mice
were anesthetized with an intraperitoneal injection of 60 μl
xylazine/ketamine mixture containing 95 mg ketamine and 5 mg
xylazine per kilogram of body weight and infected. For the
infection studies, 24 mice (eight for each group) were infected
intranasally with 5× 105 cells/20μl ofWT,sgl1 orsgl1+SGL1
reconstituted strain. Mice were inspected twice a day and those
that appeared moribund or in pain were sacriﬁced with CO2
inhalation followed by cervical dislocation. All animal procedures
were approved by Stony Brook University Institutional Animal
Care and Use Committee and followed the guidelines of
American Veterinary Medical Association. For tissue burden
analysis, four mice per strain were used. Lung, brain, liver, kidney
and spleen were excised and homogenized in 10 ml of PBS using
Stomacher 80 (Seward, UK) for 2 min at high speed. Several
dilutions were plated in duplicate onto YPD agar plates and
incubated for 48–72 h at 30◦C. TheCFUs per organ were counted.
For histopathology analysis, threemice per strain were used.Mice
organs were ﬁxed in 3.7% of formaldehyde in paraﬃn and stained
with haematoxylin and eosin and mucicarmine.
For in vivo vaccination studies, mice were pre-treated with
vehicle (PBS), sgl1 (5 × 105 cells), and gcs1 (5 × 105 cells).
After 30 days, mice pre-treated with vehicle or sgl1 were
challenged with 5 × 105 cells of Cn WT or Cg R265. Mice pre-
treated with gcs1 were challenged with 5 × 105 cells of CnWT.
Mouse survival was monitored for 80 days after post-challenge.
CD4+ T-cell depletion was achieved by weekly intraperitoneal
administration of anti-CD4+ (GK1.5, rat IgG2b, 200 μg in
200 μL of PBS; National Cell Culture Center, Minneapolis, MN,
USA). A rat IgG2b (eBioscience, Inc., San Diego, CA, USA) was
used as control. T-cell depletion was assessed by ﬂow cytometry in
the spleens. For vaccination studies, mice (eight for each group)
were pre-treated with vehicle (PBS) or sgl1 strain after 48 h
from the ﬁrst round of T-cell depletion and after 30 days were
challenged with a lethal dose of Cn WT (5 × 105 cells) and their
survival was monitored for 80 days.
Results
CNAG_05607 has Sterylglucosidase and not
Glucosylceramidase Activity
A S. cerevisiae expression system was used for characterizing
the activity of the CNAG_05607 enzyme. The blast search
of CNAG_05607 in Saccharomyces genome database revealed
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a gene YIR007W with an identity of 41% (expect = 1.8e-
129) to CNAG_05607 (Supplementary Figure S1). Therefore,
a ScYIR mutant strain lacking of YIR007W gene was used
for the studies. CNAG_05607 was cloned in pYES/CT vector
and overexpressed in S. cerevisiae YIR007W mutant strain
(ScYIR + Cn 5607). As a negative control, ScYIR mutant
was transformed with pYES/CT empty vector (ScYIR + empty
vector). Total proteins were extracted from S. cerevisiae strains,
which contained the empty vector (control) or overexpressed
the CNAG_05607 enzyme, and were incubated with plant
(Figure 1A) or cryptococcal sterylglucosides (SGs; Figure 1B).
With either substrate, 100 μg of total protein extract was
enough to signiﬁcantly degrade the SGs as evidenced by the
disappearance of the SGs band on the TLC. No diﬀerence in
the intensity of the SGs band was detected compared to the SG
control when ScYIR mutant strain carrying the empty vector
was incubated with plant or cryptococcal SGs. The activity of the
enzyme was dependent on pH (Figure 1C) and temperature (data
not shown), with the maximum activity observed at a pH 4.5 in
sodium acetate buﬀer and a temperature of 37◦C. In addition
to cryptococcal SGs, the CNAG_05607 enzyme was also able
to degrade cholesterol glucoside, the mammalian form of SGs
(Supplementary Figure S2).
The CNAG_05607 enzyme has recently been characterized
as a glucosylceramidase due to its ability to hydrolyze short-
chain glucosylceramides (Watanabe et al., 2015). Our initial
biochemical characterization also showed that CNAG_05607
metabolizes short chain glucosylceramide (data not shown)
FIGURE 1 | CNAG_05607 enzyme has sterylglucosidase and not
glucosylceramidase activity. (A) Cryptococcus neoformans
CNAG_05607 (Cn 5607) metabolizes plants SGs in a dose dependent
manner and (B) metabolizes SGs extracted from Cn cells (Cn SGs).
(C) pH dependence of Cn 5607 activity, as measured based on its
ability to cleave plants SGs and produce free sterols, showed maximal
activity at pH 4.5. Results are based on the measurement of free
sterols performed by liquid chromatography–mass spectrometry (LC–MS).
Cn 5607 does not metabolize C. neoformans GlcCer (Cn GlcCer) as
analyzed by (D) thin layer chromatography (TLC) or by (E) LC–MS
(Cerezyme is an analog of the human enzyme β-glucocerebrosidases,
and was used as a positive control). Cn 5607 is the
endoglycoceramidase-related protein 2 (EGCrP2) also identified by
Watanabe et al. (2015). Empty V, empty vector.
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similarly to what was observed by Watanabe et al. (2015).
However, CNAG_05607 did not metabolize long-chain,
physiologically relevant, 8-C9 methyl glucosylceramides
(Figures 1D,E), which is the form of glucosylceramide found in
C. neoformans. To the best of our knowledge, glucosylceramide
synthase and glucosylcerebrosidase, do not need a co-factor
or activator to exert their activity on long chain GlcCer
(i.e., C16 GlcCer; Akiyama et al., 2013). Cerezyme, a human
recombinant glucosylcerebrosidase, was used as control. This
enzyme metabolized NBD-C6-GlcCer (data not shown) as well
as long-chain Cryptococcus8-C9 methyl glucosylceramides
resulting in ceramide production (Figure 1E). Cerezyme did not
exhibit activity on plants or cryptococcal SGs (data not shown).
Thus, these results demonstrate that CNAG_05607 has speciﬁc
activity toward sterylglucosides, therefore we re-named this
enzyme Sterylglucosidase 1 (Sgl1).
Deletion of SGL1 Causes Accumulation of SGs
and not GlcCer
Since the Sgl1 enzyme acts to metabolize cryptococcal SGs,
deletion of this enzyme in C. neoformans should lead to a SGs
accumulating strain. This hypothesis was tested by genetically
eliminating the sterylglucosidase enzyme (Supplementary Figure
S3) in C. neoformans and monitoring the lipid proﬁle by
performing TLC and GC–MC on the total lipids extracted from
the WT and the mutant strain. It was found that while the WT
C. neoformans produces very little SGs, genetic elimination of
sterylglucosidase (the sgl1 mutant) leads to a dramatic SGs
accumulation; a phenomenon that is restored in the reconstituted
strain (sgl1+SGL1; Figures 2A,B). In agreement with the in
vitro activity studies, elimination of sterylglucosidase did not
aﬀect glucosylceramide levels in the cell (Figure 2C), further
conﬁrming the sterylglucosides-speciﬁc activity of this enzyme.
In depth analysis of the MS spectrum of sgl1 strain showed
the accumulation of 9 structures (Figure 2B) with ion fragments
of m/z 147, 204, 217, 305, 361, 451. These structures were
characteristic of tetramethylsilyl (TMSi) glucose ion fragments
resulting from cleavage of C–O bonds. The fragments with
m/z 361 and 451 are representative of TMSi derivative of
hexoses. Ion fragments with m/z 129 and 255, characteristic
of steroid moiety, were also present. Ion fragments with m/z
of 73 and 147 represent the cleavage of 1 TMSi and 2 TMSsi
groups respectively. The signal intensity of ion m/z 204 was
greater than 217, which represented pyranoside conﬁguration
of the O-glycosidic linkage. These ion fragments resembled the
fragmentation pattern generated during the MS analysis of plant
sterylglucosides (Gutierrez and del Rio, 2001). Altogether, the
ion fragments analysis conﬁrmed that the structure possessed all
FIGURE 2 | Deletion of SGL1 causes accumulation of SGs and not
GlcCer. Analysis of sterylglucosides (SGs) and glucosylceramide (GlcCer)
was performed by (A) TLC and (B,C) gas chromatography-mass
spectrometry. Results show that the sgl1 mutant dramatically
accumulates SGs (A,B), which are normally undetectable in wild-type (WT)
or reconstituted strain (sgl1+ SGL1). In contrast, the level of GlcCer
(A,C) in the sgl1 mutant is identical to the one observed in the WT or
sgl1+SGL1 reconstituted strain. Chromatograms are representatives of
three separate experiments showing similar results. Peaks denote: (1)
Dehydroergosteryl-β-D-glucoside∗ ; (2) Ergosteryl-β-D-glucoside; (3)
Ergosta-7,22-dien-3-oyl-β-D-glucoside∗ ; (4) Fecosteryl-β-D-glucoside∗ ; (5)
Episteryl-β-D-glucoside∗ ; (6) Lanosteryl-β-D-glucoside∗ (∗ : putative
structures). (D) Structure and electron-impact (EI) mass spectrum of peak
number 2.
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characteristics of sterylglucosides. One of the most accumulated
structures in the sgl1 mutant was ergosterolglucoside (Peak
2, Figure 2B). Apart from other characteristic ion fragments
of sterolglucoside, MS fragmentation of peak 2 showed an ion
fragment of m/z 378, which results from the cleavageC–O linkage
of O-linked glucose moiety and is characteristic to ergosterol,
suggesting that ergosterolglucoside was the structure with the
highest concentration in the sgl1 strain. The chemical structure
and the electron-impact mass spectrum of this molecule is
presented in Figure 2D.
Sgl1 is a Virulence Factor of C. neoformans
Alterations in sphingolipid metabolism have been shown to
attenuate cryptococcal virulence (Rittershaus et al., 2006; Singh
et al., 2012). Thus, the virulence of the sgl1 strain in the
mouse model of cryptococcosis was tested. Mice were infected
with a lethal dose of fungal cells (5 × 105 cells) to establish
cryptococcosis and monitored for their survival. The average
survival of mice infected with the WT C. neoformans was
24 ± 6 days whereas all mice infected with sgl1 strain remained
alive during the course of the experiment (i.e., 90 days post-
infection). Mice infected with the sgl1+SGL1 strain showed
a survival pattern similar to that observed in the WT (average
survival of 21 ± 7 days; Figure 3A). During the course of
infection, lungs and brains were removed from the mice infected
with the three strains and analysis of tissue burdenwas performed
at days 0, 3, 6, 9, and 14 post-infection.
Interestingly, the number of sgl1 cells in the lungs decreased
starting at day 3 and continued until day 14, at which point
the lungs were completely clear of fungal cells (Figure 3B).
Furthermore, no sgl1 cells were observed in the brain
(Figure 3C), suggesting that fungal cells did not disseminate to
the brain in the sgl1-infected mice. In contrast, a signiﬁcant
number of fungal cells were found in the lungs and brains
of mice infected with the WT or the sgl1+SGL1 strain
(Figures 3B,C). In both cases, the number of fungal cells in
the brain increased as a function of time, demonstrating the
occurrence of extrapulmonary dissemination and progression
of the disease. The ﬁndings of the tissue burden studies were
conﬁrmed by lung and brain histology observations, which
showed no fungal cells in the organs isolated from the sgl1-
infected mice at the end of the experiment, but signiﬁcant tissue
damage and presence of fungal cells in the WT or sgl1+SGL1
strains (Supplementary Figure S4). These experiments reveal that
sterylglucosidase is a virulence factor in C. neoformans, as the loss
of this enzyme leads to loss of virulence in the mouse model.
The sgl1 Strain Acts as a Vaccine Against
Cryptococcosis in the Mouse Model
Cryptococcus neoformans cells possess a number of virulence
factors that contribute to their survival inside the host, resistance
to immune response, and detrimental activity against the host
(Coelho et al., 2014). To gain more insight into the loss of
virulence of thesgl1 strain, a number of virulence factors in this
strain were evaluated and compared to the WT. In comparison
to the WT, the sgl1 strain showed similar growth in acidic
and neutral pH (at 37◦C and in the presence of 5% CO2),
similar melanin production and capsule thickness, and no major
diﬀerence in growth under oxidative or nitrosative stress. In
addition, the WT and mutant strains showed similar intracellular
growth during in vitro infection of the J774.16 macrophage-like
cells (Supplementary Figure S5). These analyses suggest that the
most common virulence factors are similar between the sgl1
strain and the WT denoting a diﬀerent mechanism for the loss
of virulence.
Given that the sgl1 strain was non-pathogenic and that SGs
are known immunostimulators (Lee et al., 2007; Grille et al.,
2010), the potential use of the sgl1 strain as a vaccine against
cryptococcosis was investigated. Two controls were used for these
studies: a vehicle (sterile PBS) and the C. neoformans gcs1
strain (Rittershaus et al., 2006), which is avirulent, but does not
accumulate SGs. Mice were infected with the vehicle, or 5 × 105
cells of the gcs1 or the sgl1 strains and after 30 days were
challenged with a lethal dose of the virulent WT C. neoformans
FIGURE 3 | Deletion of the SGL1 gene in C. neoformans abolishes
virulence. (A) Virulence studies showed that 100% of mice infected with
sgl1 survived the infection whereas mice infected with C. neoformans
WT H99 or with sgl1+SGL1 reconstituted strain succumbed to infection
within 24 ± 6 and 21 ± 7 days, respectively; n = 8 mice in each
group. (B) Lung tissue burden analysis showed that the sgl1 mutant is
eliminated from the lungs after 14 days of inoculation; n = 3 mice each
at time point. (C) Brain tissue burden analysis showed that sgl1 is not
found in the brain at anytime during the course of experiment; n = 3
mice at each time point.
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or C. gattii R265 strains. Interestingly, the mice that were pre-
treated with the sgl1 strain were completely protected against
the subsequent infection. However, the mice that were pre-
treated with the vehicle or the gcs1 strain succumbed to
infection within 35 days (Figure 4A). These results suggest that
the sgl1 strain may stimulate a host immune response that
successfully killssgl1 andmakes the host resistant to subsequent
cryptococcosis.
Although Cryptococcus infections can aﬄict
immunocompetent individuals, the majority of the population
at risk, are those suﬀering from immune suppression, such
as HIV/AIDS patients. A reduction in CD4+ T-cells in this
population results in aggressive cryptococcosis, which can be life
threatening (Jarvis et al., 2013). The eﬃciency of the sgl1 strain
as a vaccine against cryptococcosis during immune suppression
was examined by its administration in CD4+ T-cells depleted
mice prior to infection with the WT C. neoformans. For these
studies, mice were depleted of CD4+ by weekly administration
of anti-CD4+ antibody or control antibody (rat IgG2b) starting
a month prior to infection with WT C. neoformans (Figure 4B).
A 94.3% percent reduction in CD4+ T-cells was achieved as
conﬁrmed by ﬂow cytometry (Figure 4C). The sgl1 strain or
control (PBS) were also administered to mice a month prior
to infection. Mice were then infected with 5 × 105 cells of the
virulent WT C. neoformans. All mice that received the PBS and
the antibody control succumbed to infection in 41 days, while
all the CD4+ T-cells depleted mice that were vaccinated with
the sgl1 strain survived the infection, demonstrating that this
strain is not infectious and can protect immune suppressed mice
against a subsequent cryptococcal infection (Figure 4B).
Discussion
In the current study, a mutant C. neoformans strain lacking
the enzyme sterylglucosidase 1 (Sgl1) was engineered and
characterized. This strain accumulated SGs and was not virulent
in the mouse model, despite not demonstrating any deﬁciency
in commonly known cryptococcal virulence factors. Importantly,
this strain acted as a vaccine and was able to protect CD4+
T-cells depleted and immunocompetent mice against subsequent
infections with lethal doses of C. neoformans or C. gattii.
Deletion of the Sgl1 enzyme was used as a strategy to
accumulate SGs in C. neoformans. The presence of this
enzyme was recently reported in C. neoformans and found to
hydrolyze both SGs and short chain glucosylceramide (Watanabe
et al., 2015). However, our results provided a more thorough
characterization because it included physiologically relevant
FIGURE 4 | Vaccination studies. (A) Mice were “pre-treated” with sgl1
and, after 30 days (time 0), challenged with a lethal dose of
C. neoformans wild-type H99 (Cn WT) or Cryptococcus gattii WT R265
(Cg 265). Mice exposed to sgl1 remained alive during the course of
experiment (80 days post-infection) whereas all mice that were not
exposed to sgl1 but to vehicle (PBS) or to the gcs1 mutant strain
and then challenged with Cn WT succumbed to infection within 35 days;
n = 8 mice in each group. (B) Pre-treatment with sgl1 completely
protected CD4+ T-cell depleted mice from a subsequent lethal challenge
with C. neoformans wild-type H99 (WT); n = 8 mice in each group.
Depletion of CD4+ was achieved by administering anti-CD4 (Ab) weekly
during the entire course of the experiment. The depletion was confirmed
by flow cytometry performed at the day of Cn challenge (C). Results are
representative of three separate experiments showing similar results.
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glucosylceramide species, which are produced by C. neoformans
cells. We found that Sgl1 does not metabolize long chain
glucosylceramide but only SGs.
The sgl1 mutant was not virulent in the mouse model of
cryptococcosis. In the sgl1 strain, fungal cells were killed in the
lungs within 14 days post-infection. No fungal cells were found
in the brain tissue suggesting that the infection is completely
controlled by the host in the lungs. It is important to note that
the reduction in the fungal burden in the lungs starts at 3 days
post-infection. This is due to the fact that the sgl1 strain does
not show an appreciable growth defect compared to the WT
and exhibits a similar resistance proﬁle to stresses. Thus, the
delay in the reduction of fungal burden is due to the time it
takes for this strain to stimulate the immune response, which
then kills the strain in vivo. Given that the loss of Sgl1 does
not aﬀect the growth proﬁle or the common virulence factors of
C. neoformans, this enzyme appears to be a stand-alone factor
in controlling cryptococcal virulence. This is conﬁrmed by the
observation that the virulence phenotype was restored in the
reconstituted strain (sgl1+SGL1). The Sgl1 enzyme was active
at physiological temperature and in the pH range of 4.5 to 8.
The maximum activity was observed at pH = 4.5 after which
the activity was sharply reduced with increased alkalinity. These
activity proﬁles suggest that Sgl1 is highly active in the acidic
environment inside alveolar macrophages; the activity is also
present, although signiﬁcantly reduced, in slightly acidic/neutral
environment within the alveolar spaces.
Administration of the SGs accumulating sgl1 strain proved
to be an eﬀective vaccination strategy in the mouse models
of cryptococcosis. When administered 30 days prior to the
challenge, this strain was able to protect mice against subsequent
infections with either WT C. neoformans H99 and C. gattii R265.
These ﬁndings suggest that protection by the sgl1 strain is
not serotype speciﬁc. Protection against the C. gattii R265 is of
particular interest. The immune response against this strain is
diﬀerent from C. neoformans (Dong and Murphy, 1995; Wright
et al., 2002; Cheng et al., 2009) and it has been the subject of
a recent study for vaccination (Chaturvedi et al., 2014). It is
important to note that the Sgl1 enzyme is capable of hydrolyzing
cholesterol glucoside as well. Thus, although not experimentally
tested, it is also possible that infection with this strain might
lead to the uptake and accumulation of cholesterol glucoside
from the host, which would be otherwise metabolized by the
WT C. neoformans. However, it appears unlikely that cholesterol
glucoside accumulation would contribute to immunity against
the infection. The bacterium Helicobacter pylori routinely
accumulates cholesterol glucosides during the infection of the
mammalian host without eliciting any form of lipid-induced
immunity (Wunder et al., 2006).
The sgl1 strain was also able to protect CD4+ T-cell
depleted mice against cryptococcosis. SGs have been shown to
enhance T-cell proliferation (Bouic et al., 1996) and promote
Th1 immune response (Lee et al., 2007). A switch to Th1
cell-mediated immunity is the predominant mode of immune
response against cryptococcosis (Decken et al., 1998; Koguchi and
Kawakami, 2002; Wormley et al., 2007). In fact, promotion of
Th1 response with an engineered interferon-gamma producing
C. neoformans has been shown to protect mice against subsequent
C. neoformans infections. Our results suggest that the immune
stimulation by SGs goes beyond the Th1 immune response
because our vaccination strategy is still eﬀective in condition
of CD4+ T cell deﬁciency. This is particularly advantageous as
cryptococcosis mostly occurs in patients with this type of immune
deﬁciency. It should be noted that while the sgl1 strain provides
complete immunity in the mouse model of cryptococcosis, the
administration of a live attenuated vaccine is associated with
challenges such as undesired secondary mutations, which might
revert the virulence (Teng et al., 2013). However, this strain
can be used as a valuable starting point for the development
of other vaccine formulations such heat-killed strains or vesicle
formulations containing SGs, which would eliminate the dangers
of using a live vaccine.
The immunomodulatory properties of SGs have been
documented not only in the context of fungal infections (Lee
et al., 2007), but also in other human diseases such as rhinitis,
sinusitis, and tuberculosis (Bouic et al., 1996; Donald et al., 1997;
Bouic, 2001). Although the underlying molecular mechanisms
remain largely unknown; an increase in the level of T cells and
cytokines induced by SG administration has been reported (Bouic
et al., 1996; Donald et al., 1997). Although our data clearly
show that the sgl1 strain accumulates SGs, we cannot rule
out the presence of parallel/consequential mechanisms for the
sgl1-induced immunity. It is possible that other factors such
as stimulation of CD4+ and CD8+ T cells are involved. The
immunological basis of protection provided by vaccination with
the sgl1 strain is an interesting topic for future studies.
Conclusion
We have provided a comprehensive biochemical study of Sgl1,
characterized the C. neoformanssgl1 strain and reported that
the Sgl1 enzyme is a virulence factor in C. neoformans. The sgl1
strain is non-pathogenic and can protect immunocompromised
mice against cryptococcosis. These results could have important
implications for future vaccine development for cryptococcosis
and other fungal infections.
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